Estradiol levels in breast cancer patients on hormone therapy
Part of Cancer, Skin clinical trials.
This study measures estradiol (a female hormone) levels in breast cancer patients receiving hormone therapy. It helps doctors understand how well different treatments are working and may guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have breast cancer that was confirmed by a biopsy.
- You are either being treated for early breast cancer (naturally or medically induced menopause) OR advanced breast cancer using specific hormone-blocking drugs (letrozole, anastrozole, or exemestane) with or without a CDK4/6 inhibitor (like palbociclib) or the drug fulvestrant.
- You need a blood test to check your estradiol (a type of estrogen) levels.
- You are not currently taking tamoxifen (a different hormone therapy).
- If you have advanced breast cancer, you have not received more than one prior hormone therapy line (for AI or fulvestrant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.